Group 1 - Novo Nordisk announced the acquisition of Akero Therapeutics for up to $5.2 billion to enhance its portfolio with a promising experimental liver disease drug [1] - This acquisition marks the first major deal for the Danish drugmaker in its strategic expansion efforts [1] - The deal reflects Novo Nordisk's commitment to addressing liver diseases, which are becoming increasingly prevalent [1] Group 2 - Akero Therapeutics is based in the U.S. and is known for its innovative approaches to treating liver conditions [1] - The acquisition is expected to bolster Novo Nordisk's research and development capabilities in the liver disease segment [1] - This move aligns with industry trends focusing on specialized treatments for chronic diseases [1]